Ignite Creation Date:
2024-05-05 @ 12:02 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00214253
Status:
COMPLETED
Last Update Posted:
2017-03-31
First Post:
2005-09-14
Brief Title:
Islet Transplantation in Type 1 Diabetic Patients
Sponsor:
University of Wisconsin Madison
Organization:
University of Wisconsin Madison
Study Overview
Official Title:
Islet Transplantation in Type 1 Diabetic Patients Using a Steroid-free Immunosuppression Protocol and Thiazolidinedione Insulin Sensitizers
Status:
COMPLETED
Status Verified Date:
2017-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Our hypothesis is that a successful clinical islet transplant program can be established at the University of Wisconsin using a steroid -free sirolimus- and low dose tacrolimus - based immunosuppressive drug regimen Edmonton protocol We intend to answer the following research questions 1 will treatment of islet transplant recipients with thiazolidinediones ie pioglitazone enhance post-transplant islet function and reduce the number of islets necessary to achieve adequate metabolic control 2 which type 1 diabetic patients are optimal candidates for islet transplantation ie islet transplant alone or islet after kidney transplantation 3 Can cadaver donor pancreases which are ordinarily discarded and not used for pancreas transplantation be used for islet transplantation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None